Individualized Medication Guidance for Gynecologic Cancer

According to the latest Chinese women's new cancer statistics, cervical cancer and ovarian cancer are in the top ten new cases of female cancer (about 110,000 and 60,000 respectively). With the widespread clinical use of poly(ADP-ribose) polymerase (PARP) inhibitors, the progression-free survival (PFS) of ovarian cancer patients has been significantly prolonged. At present, the biomarkers related to PARP inhibitor treatment mainly include BRCA1/2 gene mutation, HRR gene mutation, etc., and some studies have found that about 50% of epithelial ovarian cancer patients have homologous recombination deficiency (homologous recombination deficiency, HRD).